Leaflet IRINOTECAN KOANAA 20mg / ml concentrate for solution for infusion
Indicated for: colorectal cancer
Route of administration: infusion
Substance: irinotecan (topoisomerase inhibitor)
ATC: L01XX19 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
This medicine may affect fertility.
Handle with special care.
Seek medical advice if severe or persistent diarrhea occurs.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
A genetic test may be needed before treatment.
Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
General data about IRINOTECAN KOANAA 20mg / ml
- Substance: irinotecan
- Date of last drug list: 01-01-2021
- Commercial code: W67177001
- Concentration: 20mg / ml
- Pharmaceutical form: concentrate for solution for infusion
- Quantity: 1
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for irinotecan
Concentrations available for irinotecan
- 1.5mg/ml
- 20mg/ml
- 4.3mg/ml